Global Benign and Malignant Soft Tissue Tumors Treatment Market – Industry Trends and Forecast to 2029

Análise e dimensão do mercado de tratamento de tumores de tecidos moles benignos e malignos

A ocorrência de tecidos moles benignos é dez vezes superior à dos malignos. Quase 45% dos tumores de tecidos moles desenvolvem-se nas extremidades inferiores, 15% no retroperitoneu, 10% na região da cabeça e pescoço, 15% nas extremidades superiores e os restantes 15% na parede abdominal e torácica. Os tumores de tecidos moles afetam adultos e crianças, embora a ocorrência de tumores de tecidos moles ajustada à idade varie entre os 15 e os 35 anos por cada 1 milhão de habitantes.

A Data Bridge Market Research analisa uma taxa de crescimento no mercado global de tratamento de tumores benignos e malignos de tecidos moles no período de previsão 2022-2029. O CAGR esperado do mercado global de tratamento de tumores benignos e malignos de tecidos moles tende a rondar os 11% no período de previsão mencionado. O mercado foi avaliado em 2,07 milhões de dólares em 2021 e cresceria até 4,77 milhões de dólares até 2029. Para além dos insights de mercado, como o valor de mercado, taxa de crescimento, segmentos de mercado, cobertura geográfica, participantes no mercado e cenário de mercado, o O relatório de mercado com curadoria da equipa de pesquisa de mercado da Data Bridge inclui também uma análise especializada aprofundada, epidemiologia dos doentes, análise de pipeline, análise de preços e estrutura regulamentar.

Âmbito e segmentação do mercado de tratamento de tumores de tecidos moles benignos e malignos

Definição de mercado

Os tumores de tecidos moles compreendem um grupo grande e heterogéneo de neoplasias. Os tumores de tecidos moles crescem centrípetamente, embora alguns tumores benignos possam crescer longitudinalmente ao longo dos planos dos tecidos. A maioria dos tumores de tecidos moles respeita os limites fasciais, permanecendo confinados ao compartimento de origem até às fases posteriores de desenvolvimento. Os tumores de tecidos moles são classificados principalmente como malignos ou benignos, enquanto os restantes são intermédios.

Dinâmica global do mercado de tratamento de tumores de tecidos moles benignos e malignos

Motoristas

• Aumento de casos de cancro

De acordo com a American Cancer Society, cerca de 13.190 novos sarcomas de tecidos moles serão diagnosticados nos EUA em 2022 (7.590 em homens e 5.600 em mulheres). Cerca de 5.130 pessoas, das quais 2.740 homens e 2.390 mulheres deverão morrer de sarcomas de tecidos moles. Isto impulsiona o crescimento do mercado.

• Envolvimento crescente dos ensaios clínicos

As grandes necessidades não satisfeitas do mercado apresentam uma oportunidade primária para desenvolver terapias inovadoras e de primeira classe. Dos 45 medicamentos em preparação para o sarcoma, sete estão na Fase III, 22 na Fase II, dois nos ensaios de Fase I/II e os restantes na Fase I e nos ensaios pré-clínicos. O potencial papel dos agentes imuno-oncológicos nos sarcomas está a ser avaliado em ensaios clínicos de Fase I/II. Assim, todas estas iniciativas aumentam o crescimento do mercado.

Oportunidades

• Introdução de muitas terapêuticas

Durante mais de 40 anos, a base do tratamento dos tecidos moles incluiu a ressecção cirúrgica seguida de radiação ou quimioterapia neoadjuvante ou adjuvante. No entanto, mesmo após a ressecção cirúrgica completa, cerca de 50,0% dos doentes com sarcoma de grau intermédio ou elevado desenvolvem doença metastática. O tratamento quimioterápico envolve geralmente uma combinação de vários agentes antineoplásicos. Os medicamentos mais utilizados incluem a ifosfamida e a doxorrubicina. Os outros agentes quimioterápicos incluem a dacarbazina, cisplatina, eribulina, paclitaxel, oxaliplatina e vincristina.

• Aumento da Sensibilização sobre Saúde

Awareness among patients as well as healthcare providers about the incidence of soft tissue tumor is on the rise. Patients and doctors are now more actively learning about the therapies available for treating these severe diseases. This creates more opportunities in the market.

Restraints/Challenges

• Side-Effects of Soft Tissue Tumor Drugs

There are numerous side-effects associated with the soft tissue tumor drugs. Effects such as swelling under the skin, tummy, mouth sores, fatigue, nausea that highly disrupts the treatment market.

• Increasing Cost Of Treatments

The huge expenditure required for the treatment methods hamper the market growth. Many of the treatments involved in this disease require high cost and thus at times gets difficult for many people, especially the ones in the rural areas. Thus, this can act as a major hindrance factor for the market. Increasing radiotherapy and chemotherapy costs may hamper the growth of the global benign and malignant soft tissue tumors treatment market during the forecast period.

This global benign and malignant soft tissue tumors treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global benign and malignant soft tissue tumors treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Benign and Malignant Soft Tissue Tumors Treatment Market Scope

The global benign and malignant soft tissue tumors treatment market is segmented on the basis of treatment, type, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Types

• Benign Schwannoma
• Desmoid Tumor
• Lipoblastoma
• Lipoma
• Solitary
• Uterine Leiomyoma
• Clear Cell Sarcoma
• Dermatofibrosarcoma Protuberans
• Ewing Sarcoma
• Extraskeletal Myxoid Chondrosarcoma
• Liposarcoma
• Myxoid
• Liposarcoma
• Well Differentiated
• Alveolar Rhabdomyosarcoma
• Synovial Sarcoma
• Others

Treatment

• Medical Therapy
• Surgical Therapy
• Postoperative Therapy
• Long Term Monitoring
• Others

Route of Administration

• Oral
• Parenteral
• Others

End-Users

• Hospitals
• Homecare
• Speciality Centres
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Benign and Malignant Soft Tissue Tumors Treatment Market Regional Analysis/Insights

The global benign and malignant soft tissue tumors treatment market is analyzed and market size insights and trends are provided by treatment, type, route of administration, distribution channel and end-user as referenced above.

The major countries covered in the global benign and malignant soft tissue tumors treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Asia-Pacific is expected to have the highest market growth due to increased government awareness programs, and presence of generic drugs manufacturers.

North America dominates the market due to the presence of key manufacture of the product, high research & development and healthcare expenditure and skilled professionals

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Competitive Landscape and Global Benign and Malignant Soft Tissue Tumors Treatment Market Share Analysis

The global benign and malignant soft tissue tumors treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global benign and malignant soft tissue tumors treatment market.

Key players operating in the global benign and malignant soft tissue tumors treatment market include:

• F. Hoffmann-La Roche Ltd. (Switzerland)
• Mylan N.V. (U.S.)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Sanofi (France)
• Pfizer Inc. (U.S.)
• GSK plc (U.K.)
• Novartis AG (Switzerland)
• Bayer AG (Germany)
• Lilly (U.S.)
• Merck & Co., Inc. (U.S.)
• Sun Pharmaceutical Industries Ltd. (India)
• Aurobindo Pharma (India)
• Lupin (India)
• Dr. Reddy's Laboratories Ltd (India)
• Endo International plc (Ireland)

SKU-55226